BRAFV600E mutation Adverse events Langerhans cell histiocytosis Antineoplastic agents Children Immunotherapy Colon cancer Brain Metastases Gastric bypass Abscopal effect Beta-catenin Biomarkers Anti-PD1 Mesenchymal stromal cells Plasma ACTH ALK rearrangement Androgen insensitivity Polyomavirus Dabrafenib Circulating cell-free DNA Staging Abdominal pain ALK Adjuvant FOLFOX Cancer bronchique non à petites cellules Adjuvant therapy Ceritinib Biomarker Invasive cutaneous squamous cell carcinoma Diagnosis Immune checkpoint inhibitor Prognosis Biliopancreatic diversion BRAF V600-mutation EGFR Body mass index Histiocytosis Allelic imbalance Resistance Targeted therapy Advanced melanoma Merkel cell carcinoma AZD9291 Wnt Safety Metastatic cSCC Bariatric surgery Cell signalling Cemiplimab BRAFV600E Lung adenocarcinoma Chemotherapy Circulating tumor DNA Non-small cell lung cancer CARMN Cancers of the Colon Cancer Stem Cells Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy Molecular targeted therapies Radiofrequency ablation Advanced BRAF V600E Anti-PD-1 antibody BRAF Antibody-drug conjugate Systemic therapy Immunomodulation Nivolumab Colorectal cancer Chemoresistance BRAFV600-mutant melanoma Cancer Acute generalized exanthematous pustulosis AML Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian Prognostic Anti-PD1 blockade Radiotherapy Anti-PD-1 Anti-Tumor pharmacology Sonic Hedgehog Adjuvant COVID-19 C797S Bone marrow niche Survival Adjuvant Anti-PD-1 antibody Cemiplimab Cutaneous squamous cell carcinoma Follow-up Locally advanced Metastatic Radiotherapy Surgical excision Treatment Crizotinib Melanoma TNM classification Prevention Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation Immunohistochemistry 2-chlorodeoxyadenosine Trametinib Anti-CTLA-4 ADN tumoral circulant Colorectal carcinoma Osimertinib